Medicare AdvantageAdministrativeMedium impact
New Part D Star Measures – Concurrent Use of Opioid and Benzodiazepine, and Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults
Blue Cross Blue Shield of Rhode Island·Family Medicine, Internal Medicine, Geriatrics +2 more·Physician
Effective date
Mar 1, 2025
We identified it
Jun 19, 2026
Summary
CMS introduced two new Part D Star Measures for 2025 to improve medication safety for older adults: one tracking concurrent opioid and benzodiazepine use, and another monitoring use of multiple anticholinergic medications. These measures align with American Geriatrics Society Beers Criteria and will impact quality ratings for Medicare Part D plans.
Action Required
By March 1, 2025: Providers must review prescribing patterns for patients 18+ receiving both opioids and benzodiazepines concurrently for 30+ days, and patients 65+ taking multiple anticholinergic medications for 30+ days. Update clinical workflows to include medication review protocols, coordinate care between prescribing providers, and document alternative therapies considered. Billing team should prepare for potential quality measure reporting requirements that may affect Medicare Part D plan ratings.